Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia.

Duployez N, Chebrek L, Helevaut N, Fournier E, Bemba M, Caillault A, Geffroy S, Preudhomme C.

Haematologica. 2018 Jun 14. pii: haematol.2018.190959. doi: 10.3324/haematol.2018.190959. [Epub ahead of print] No abstract available.


High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.

Salson M, Giraud M, Caillault A, Grardel N, Duployez N, Ferret Y, Duez M, Herbert R, Rocher T, Sebda S, Quief S, Villenet C, Figeac M, Preudhomme C.

Leuk Res. 2017 Feb;53:1-7. doi: 10.1016/j.leukres.2016.11.009. Epub 2016 Nov 21.


Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.

Ferret Y, Caillault A, Sebda S, Duez M, Grardel N, Duployez N, Villenet C, Figeac M, Preudhomme C, Salson M, Giraud M.

Br J Haematol. 2016 May;173(3):413-20. doi: 10.1111/bjh.13981. Epub 2016 Feb 21.


L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.

Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T.

Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. French. No abstract available.


EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.

Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F.

Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970.


Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.

Giraud M, Salson M, Duez M, Villenet C, Quief S, Caillault A, Grardel N, Roumier C, Preudhomme C, Figeac M.

BMC Genomics. 2014 May 28;15:409. doi: 10.1186/1471-2164-15-409.


Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.

Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.

Am J Hematol. 2014 Jun;89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8.


["I feel reassured, the SAMSAH is there for me"].

Caillault AM.

Rev Infirm. 2013 Dec;(196):28. French.


Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.

Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AM, Jensen JL, Jensen KM, Marcussen N, Orntoft TF.

Clin Cancer Res. 2007 Jun 15;13(12):3545-51.


Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, Diez de Medina SG, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F.

Carcinogenesis. 2006 Apr;27(4):740-7. Epub 2005 Dec 7.


Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor.

Bernard-Pierrot I, Ricol D, Cassidy A, Graham A, Elvin P, Caillault A, Lair S, Broët P, Thiery JP, Radvanyi F.

Oncogene. 2004 Dec 9;23(57):9201-11.


Supplemental Content

Loading ...
Support Center